ArticleDiscover oncology2025
A comprehensive pan-cancer analysis of the prognostic role and immunotherapy efficacy evaluation of Glyoxalase 1.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aldehyde Detoxification in Cancer: Metabolic Guardians of the Genome.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundGlyoxalase 1 (GLO1), an enzyme responsible for breaking down methylglyoxal (MG), is increasingly recognized as a tumor-promoting factor due to its role in removing cytotoxic MG. This study aims to analyze the expression status and prognostic significance of GLO1 across various cancers and explore its potential role in cancer immunotherapy.
methodsWe obtained GLO1 mRNA expression profiles from The Cancer Genome Atlas (TCGA) database. Kaplan-Meier analysis was used to evaluate the prognostic value of GLO1 in multiple cancers. We validated GLO1 protein expression in clinical endometrial cancer samples using immunohistochemical staining. Additionally, we analyzed GLO1's correlation with drug sensitivity from the Genomics of Drug Sensitivity in Cancer (GDSC) database and its relationship with the tumor microenvironment and immunotherapy response.
resultsGLO1 was widely expressed in human tumor tissues with significant differences compared to adjacent normal tissues. High GLO1 expression was associated with poor prognosis in 14 cancers, including adrenocortical carcinoma, cholangiocarcinoma, and lymphoid neoplasm diffuse large B-cell lymphoma. GLO1 expression was negatively related to immune cell infiltration in breast invasive carcinoma. In melanoma and kidney renal clear cell carcinoma, high GLO1 expression was linked to poor immunotherapy outcomes.
conclusionsThis comprehensive pan-cancer study reveals the prognostic value and potential predictive role of GLO1 in immunotherapy across multiple tumor types. This study primarily utilized bioinformatic datasets; experimental validation was performed for endometrial cancer but warrants expansion to other cancer types in future work.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.